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A B S T R A C T
Background
Cataract is the leading cause of world blindness. The only available treatment for cataract is surgery. Surgery requires highly-trained
individuals with expensive operating facilities. Where these are not available, patients go untreated. A form of treatment that did not
involve surgery would be a useful alternative for people with symptomatic cataract who are unable or unwilling to undergo surgery. If
an eye drop existed that could reverse or even prevent progression of cataract, then this would be a useful additional treatment option.
Cataract tends to result from oxidative stress. The protein, L-carnosine, is known to have an antioxidant effect on the cataractous lens,
so biochemically there is sound logic for exploring L-carnosine as an agent to reverse or even prevent progression of cataract. When
applied as an eye drop, L-carnosine cannot penetrate the eye.However, when applied to the surface of the eye,N-acetylcarnosine (NAC)
penetrates the cornea into the front chamber of the eye (near to where the cataract is), where it is metabolised into L-carnosine. Hence,
it is possible that use of NAC eye drops may reverse or even prevent progression of cataract, thereby improving vision and quality of
life.
Objectives
To assess the effectiveness of NAC drops to prevent or reverse the progression of cataract.
Search methods
We searched CENTRAL (which contains the Cochrane Eyes and Vision Trials Register) (2016, Issue 6), Ovid MEDLINE, Ovid
MEDLINE In-Process and Other Non-Indexed Citations, Ovid MEDLINE Daily, Ovid OLDMEDLINE (January 1946 to June
2016), Embase (January 1980 to June 2016), Allied and Complementary Medicine Database (AMED) (January 1985 to June 2016),
Cumulative Index to Nursing and Allied Health Literature (CINAHL) (1982 to June 2016), the ISRCTN registry (www.isrctn.com/
editAdvancedSearch), ClinicalTrials.gov (www.clinicaltrials.gov) and the World Health Organization (WHO) International Clinical
Trials Registry Platform (ICTRP) (www.who.int/ictrp/search/en). We did not use any date or language restrictions in the electronic
searches for trials. We last searched the electronic databases on 28 June 2016. We handsearched the American Society of Cataract
and Refractive Surgery (ASCRS) and the European Society of Cataract and Refractive Surgeons (ESCRS) meetings from 2005 until
September 2015.
Selection criteria
We planned to include randomized or quasi-randomised controlled trials where NAC was compared to control in people with age-
related cataract.
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Data collection and analysis
We used standard methodological procedures expected by Cochrane.
Main results
We identified two potentially eligible studies from Russia and the United States. One study was split into two arms: the first arm ran
for six months, with two-monthly follow-up; the second arm ran for two years with six-monthly follow-up. The other study ran for
four months with a data collection point at the start and end of the study only. A total of 114 people were enrolled in these studies.
The ages ranged from 55 to 80 years.
We were unable to obtain sufficient information to reliably determine how both these studies were designed and conducted. We have
contacted the author of these studies, but have not yet received a reply. Therefore, these studies are assigned as ‘awaiting classification’
in the review until sufficient information can be obtained from the authors.
Authors’ conclusions
There is currently no convincing evidence that NAC reverses cataract, nor prevents progression of cataract (defined as a change in
cataract appearance either for the better or for the worse). Future studies should be randomized, double-masked, placebo-controlled
trials with standardised quality of life outcomes and validated outcome measures in terms of visual acuity, contrast sensitivity and glare,
and large enough to detect adverse effects.
P L A I N L A N G U A G E S U M M A R Y
N-acetylcarnosine (NAC) drops for age-related cataracts
What is the aim of this review?
The aim of this Cochrane Review was to find out if NAC eye drops can prevent or reverse the progression of cataracts (cloudy lens in
the eye).
Key messages
It is uncertain whether NAC eye drops prevent, or reverse, the progression of cataracts.
What was studied in the review?
The eye has a clear lens that focuses the light on the back of the eye. As people get older this lens can become cloudy, leading to vision
problems. A cloudy lens is known as a cataract. Doctors can remove the cataract and replace it with an artificial lens. This is usually a
very successful operation. But any operation has risks and can be an unpleasant experience. Cataracts are common in older populations
and cataract surgery is expensive for health care systems. This is why there is interest in preventing, or treating cataract, so that surgery
can be avoided.
As part of normal metabolism, our bodies produce chemicals that contain oxygen and are reactive (“reactive oxygen species”). One
theory of ageing is that these chemicals may be harmful and might lead to age-related changes in our body, such as cataract. This is
known as oxidative stress. N-acetylcarnosine (NAC) is thought to be able to combat some of the effects of oxidative stress as it has anti-
oxidant properties. If NAC can stop the lens from becoming cloudy, or reduce the cloudiness, this might improve people’s vision and
quality of life.
What are the main results of the review?
The Cochrane researchers found two potentially relevant studies. The studies compared NAC eye drops with placebo or no treatment.
These studies were from Russia and the United States and were conducted by the same research group.The Cochrane researchers were
unable to find out enough information about these studies to include in the review. These studies are assigned as ‘awaiting classification’
in the review until sufficient information can be obtained from the authors.
How up-to-date is this review?
The review authors searched for studies that had been published up to 28 June 2016..
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B A C K G R O U N D
Description of the condition
Cataract is opacification of the lens within the eye, which can cause
symptoms due to poor, or altered quality of vision. This can lead
to a reduced ability to carry out activities of daily living, driving
and working (Steinberg 1994).
Recent figures show that cataract is responsible for 48% of world
blindness, representing some 17.6 million people making it the
leading cause of blindness (Resnikoff 2004).
Description of the intervention
Currently, the only widely-accepted treatment for cataract is re-
moval. This is done through an operation. As the cataract is the
natural lens of the eye that has reduced clarity, its removal usually
precedes replacement of the natural lens with an artificial one.
There were 320,000 cataract operations carried out in the UK
between 2012 and 2013 (HSCIC 2013). In the United States,
the figure is estimated at 1.7 million operations carried out in
Medicare beneficiaries in 2004 (Schein 2012).
Currently there is no treatment for cataracts aside from surgery.
One of the causes of cataract may be oxidative stress within the
lens. Oxidative stress results from the formation of free radical
species. Carnosine is a naturally occurring dipeptide, implicated
in reducing free radicals in the body (Dahl 1988).
Anti-cataract drops are instilled onto the affected eye twice a day.
A course of treatment is recommended for a minimum of two
months and may be required indefinitely to prevent progression
of the cataract.
How the intervention might work
Topical application of carnosine onto the ocular surface does not
result in penetration into the eye. Hence, a vehicle has been de-
veloped, called N-acetylcarnosine (NAC). When NAC is instilled
onto the eye it penetrates the anterior chamber of the eye through
the cornea. Subsequent metabolism of NAC within the eye pro-
duces L-carnosine, the active drug (Babizhayev 1996).
L-carnosine has been shown to have an antioxidant effect on the
cataractous lens (Babizhayev 1989). Consequently, it is possible
that topical administration of NAC could lead to a reduction in
cataract by either slowing down the progression of the cataract or
indeed reversing the cataractous change.
Why it is important to do this review
The current forms of management are either conservative (do
nothing) or surgical. The cataract(s) may cause the patient to cease
or downgrade certain activities such as driving, working and self-
caring.
Overall success rates for cataract surgery include 95% of patients
being satisfied with the results of the surgery (Lum 2000); the
quoted risk of sight-threatening infection is 0.1% (Montan 2002).
In high-income countries a medical treatment or prophylactic
agent such as NAC eye drops would add to the treatment op-
tions available to the ophthalmologist and medical practitioners
in the primary care setting; fewer people may need to consult an
ophthalmologist and of those who did, fewer may require surgery.
Individuals may be able to choose which treatment option they
prefer and fewer surgical complications would arise from fewer
operations. In countries with emerging economies, it may mean
the difference between survival and death. Ultimately, more peo-
ple may have improved vision and fewer may have worse vision.
It is important to identify whether the evidence supports the the-
ory. There are multiple freely-available brands of eye drops pur-
ported to reverse cataract. These can be obtained without prescrip-
tion and over the Internet. Unless there is evidence to support
their use, they should not be distributed. Conversely, manufactur-
ers of machinery, consumables and intraocular lenses relevant to
cataract surgery may not be motivated to advance research in this
field or share study results due to the possible loss of income that
would follow the successful use of such an eye drop. Conducting
this review could eliminate this bias.
O B J E C T I V E S
To assess the effectiveness of carnosine to prevent or reverse the
progression of cataract.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included all randomized and quasi-randomised controlled tri-
als. We excluded cross-over trials due to the uncertainty regarding
carry-over effects.
Types of participants
We included trials where participants are over 50 years of age with
measurable cataract, specifyingwhich eye is affected (or both eyes),
as defined by a suitably qualifiedmedical practitioner or researcher,
which is shown to be affecting their quality of life through reduced
or abnormal vision. We did not make any demographic differen-
tiations. We excluded participants with any ocular comorbidity,
3N-acetylcarnosine (NAC) drops for age-related cataract (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
as this condition may make it difficult to diagnose the cause of
reduced vision.
Types of interventions
We included all trials where topical NAC is compared to a control
(such as saline or artificial tear) or to cataract surgery. Included
trials had a minimum treatment period of two months at any dose
and frequency.
Types of outcome measures
Primary outcomes
• Cataract appearance as defined on LOCS III grading slides
or Scheimpflug photography (pixel counting).
We planned to assess the primary outcome as short-term (less than
one year) and long-term (more than one year). Change was defined
by the trial investigators.
Secondary outcomes
• Quality of life as measured by validated quality of life
questionnaires, namely VCM1, IVI, VFQ-25, AVL, Van Dijk,
NHI, Carta, SQDL-DVI, ADVS, VF-14, VDA, CSS, TyPE,
HVAT, MIOLS VFQOL, Catquest, Mone-stam and VFI.
• Visual acuity as measured by Snellen (imperial or metric),
LogMAR or ETDRS charts.
• Contrast sensitivity as measured by validated printed
optotype or grating tests, namely Mentor B-VAT, CSV-1000,
MCT 8000, Pelli-Robson, ETDRS, Cambridge, Regan and
Joyce.
• Glare disability as measured by validated glare disability
tests, namely Mentor BAT, Miller-Nadler and Berkely glare test.
Adverse effects
As reported.
We planned to assess all secondary outcomes as short-term (less
than one year) and long-term (more than one year). Change was
defined by the trial investigators.
Search methods for identification of studies
Electronic searches
We searched CENTRAL (which contains the Cochrane Eyes
and Vision Trials Register) (2016, Issue 6), Ovid MEDLINE,
Ovid MEDLINE In-Process and Other Non-Indexed Citations,
Ovid MEDLINE Daily, Ovid OLDMEDLINE (January 1946
to June 2016), Embase (January 1980 to June 2016), Al-
lied and Complementary Medicine Database (AMED) (January
1985 to June 2016), Cumulative Index to Nursing and Al-
lied Health Literature (CINAHL) (1982 to June 2016), the IS-
RCTN registry (www.isrctn.com/editAdvancedSearch), Clinical-
Trials.gov (www.clinicaltrials.gov) and the World Health Orga-
nization (WHO) International Clinical Trials Registry Platform
(ICTRP) (www.who.int/ictrp/search/en).We did not use any date
or language restrictions in the electronic searches for trials. We last
searched the electronic databases on 28 June 2016.
See Appendices for details of search strategies for CENTRAL
(Appendix 1), MEDLINE (Appendix 2), Embase (Appendix
3), CINAHL (Appendix 4), AMED (Appendix 5 ), ISRCTN
(Appendix 6), ClinicalTrials.gov (Appendix 7) and the WHO IC-
TRP (Appendix 8) .
Searching other resources
We searched the reference lists of included studies and searched the
Science Citation Index database to identify any additional trials.
We handsearched the society meetings of the American Society
of Cataract and Refractive Surgery (ASCRS) and the European
Society of Cataract and Refractive Surgeons (ESCRS) from 2005
to September 2015.
Data collection and analysis
Selection of studies
Both review authors (VD, AB) searched through the results and
independently extracted data in duplicate.We included studies on
the basis of the criteria specified above. For studies that we labelled
as ’include’ or ’unsure’, we obtained a full-text report of the study.
We recorded the selection process in sufficient detail to complete
a PRISMA flow diagram (Moher 2009), and Characteristics of
excluded studies table. The two review authors resolved any dis-
agreement by discussion.
Data extraction and management
We designed a paper data collection form. The form consisted
of study and version ID, review author ID, citation and contact
details, confirmation of eligibility for review, any reasons for ex-
clusion of participants, study design, study duration, evidence of
sequence generation and allocation sequence concealment, mask-
ing and documentation of any concerns over bias.
• Participant factors: number, setting, diagnostic criteria, age,
sex, country and study dates.
• Intervention data: number of groups, number of
participants per group and details of intervention for all groups.
• Outcomes: quality of life (differences in scores between
baseline and study endpoint), cataract severity (differences in
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LOCS III scores and density (Scheimpflug) between baseline and
study endpoint) and visual function (differences in measured
visual acuity and contrast sensitivity between baseline and study
endpoint).
We planned to collect these data at short-term (less than one year)
and at long-term (more than one year) intervals. We based the
outcome criteria on change from the baseline; we recorded scales,
including limits and units of measurement.
• Results: any missing participants, summary data as detailed
above including means, confidence intervals and P values.
• Adverse event data: (worsening in quality of life scores,
visual function, or cataract within the study period, or adverse
effects from topical application of NAC drops, i.e. pain, eye
infection, allergy and scarring to ocular surface) and relevant
notes.
We documented sources of funding, along with key conclusions
from study authors, any references to related studies and any com-
ments from the review authors.
Both review authors independently collected all the data in dupli-
cate. One review author (VD) entered the data from both review
authors into Review Manager 5 (RevMan 2014), and the second
review author (AB) then checked that the data had been correctly
entered.
Assessment of risk of bias in included studies
We used Cochrane’s tool for assessing risk of bias as per Chapter
8 of the Cochrane Handbook for Systematic Reviews of Interventions
assessing the following (Higgins 2011): sequence generation, allo-
cation concealment, masking (blinding) of participants, personnel
and outcome assessors, incomplete outcome data, selective out-
come reporting and other sources of bias. We assessed all param-
eters as ’low’, ’high’ or ’unclear’ risk of bias.
Measures of treatment effect
Weplanned to analyse ordinal data such as visual acuity and LOCS
III grading as continuous data, using their respective standardised
mean differences (SMDs).
We planned to analyse continuous data such as cataract density
(measured by pixel counting on a Scheimpflug camera system) and
quality of life data, with respective SMDs, as the measurement
scales may vary depending upon which equipment or method(s)
are used in each study.
We planned to consider data on glare sensitivity and contrast sensi-
tivity as ordinal or continuous, depending upon the measurement
method used.
Unit of analysis issues
We included only studies where people are randomized to treat-
ment. We excluded trials where one eye receives treatment and the
other placebo.
Trialists may use two main methods to deal with the problem of
non-independence of data from eyes: (i) they may enrol one eye
per person into the trial, or (ii) they may analyse data from both
eyes making corrections for within-person correlation.
For (i), we documented the criteria used to define which eye is to
be included in the trial.
For (ii), if the trialist has not adjusted for within-person correla-
tion, we planned to take statistical advice, but as no trials were
included this is not relevant for this version of the review.
Dealing with missing data
We planned to document the reasons why participants were not
followed up, if reported. We planned to contact study trialists for
further clarification as needed. At that stage we planned to be able
to make judgements as to whether the data are missing at random
or not.We planned to address the potential impact of missing data
in the Discussion section.
Assessment of heterogeneity
We planned to investigate clinical heterogeneity by examining dif-
ferences in population, intervention and outcomes. We planned
to investigate statistical heterogeneity by looking at the forest plots
and statistical tests (Chi2 and the I2 statistic) since tests for statis-
tical heterogeneity are underpowered when the number of studies
is low.
Assessment of reporting biases
We planned to use funnel plots to help in our assessment of bias as
per Chapter 10 of the Cochrane Handbook for Systematic Reviews
of Interventions (Sterne 2011), but as there was not enough data,
we did not create funnel plots.
Data synthesis
Aswe cannot assume that the interventionwill have the same effect
in different groups of people, that is, that each included study
will be measuring the same effect, we planned to pool the data
using a random-effects model (providing there are three or more
included trials providing relevant data). A random-effects model
will allow for differences in the effect of the intervention between
the included trials. If the heterogeneity is too great, then meta-
analysis will not be possible.
Subgroup analysis and investigation of heterogeneity
We planned to consider the following subgroups but in the event
there were not enough data to do these analyses.
• Smokers versus non-smokers.
• Diabetics versus non-diabetics.
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Sensitivity analysis
We did not plan to conduct any sensitivity analysis for this review.
Summary of findings
We planned to include a ’Summary of findings’ table, but due
to the sparse and uncertain data we did not do this. In future
updates of this review, if we identify further trials, we will include a
’Summary of findings’ table including our primary and secondary
outcomes.
We assessed the overall quality of the evidence using GRADEpro
GDT (GRADEpro GDT 2014). This was done against the fol-
lowing GRADE parameters (Atkins 2004): study limitations, con-
sistency of effect, imprecision, indirectness and publication bias
.The following outcomes were assessed: cataract appearance, qual-
ity of life, visual acuity, contrast sensitivity and glare disability.
R E S U L T S
Description of studies
Results of the search
The electronic searches yielded a total of 151 references (Figure
1). The Cochrane Information Specialist removed 65 duplicate
records and we screened the remaining 86 reports. We rejected 82
records after reading the abstracts andobtained the full-text reports
of four references for assessment. All four studies were conducted
by Dr Babizhayev - after assessing the studies, we considered
Babizhayev 2002; and Babizhayev 2004 were potentially eligible
andwe excludedBabizhayev 2009 andBabizhayev 2011; see below
for details.
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Figure 1. Study flow diagram.
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Studies awaiting classification
We identified two potentially eligible studies (Babizhayev 2002;
Babizhayev 2004).
In Babizhayev 2002, 49 people (76 eyes) were enrolled in Russia
and the United States. Some participants were followed up to six
months and others to 24 months, however, the rationale for this
was not clear, and these were described as two different studies.
Participants were randomized to NAC 1% (26 people, 41 eyes) or
control. Some of the control group received placebo (13 people,
21 eyes) and others received no treatment (10 people, 14 eyes),
but again it was not clear why this was the case. Outcomes mea-
sured included cataract appearance (image analysis), visual acuity
(Snellen), a measure of glare sensitivity and adverse effects.
In Babizhayev 2004, 65 people were enrolled in the United States.
People with cataract were identified from the medical notes and
the participants were randomly allocated to NAC (35 people) or
placebo (30 people) and followed up for four months. Outcomes
included visual acuity (logMAR) and the halometer glare disability
test.
We were unable to obtain sufficient information to reliably deter-
mine how both these studies were designed and conducted. We
have contacted the author of these studies, but have not yet re-
ceived a reply. Therefore, these studies are assigned as ‘awaiting
classification’ until sufficient information can be obtained from
the authors.
Excluded studies
We excluded two studies (Babizhayev 2009; Babizhayev 2011),
and reasons for exclusion can be found in the Characteristics of
excluded studies table.
Risk of bias in included studies
No studies were found that met the inclusion criteria.
Effects of interventions
No studies were found that met the inclusion criteria.
D I S C U S S I O N
Summary of main results
Two studies potentially met the inclusion criteria for this review
but we were unable to obtain further information from the study
authors to enable us to judge whether they were eligible for inclu-
sion in the review.
Overall completeness and applicability of
evidence
There is insufficient good quality evidence to be able to answer
the review question.
Potential biases in the review process
We followed procedures expected by Cochrane.
Agreements and disagreements with other
studies or reviews
Other reviews currently focus on the biochemical and structural
aspects of cataractogenesis. As far as we are aware there have been
no other independent assessment of the clinical trials of NAC
drops in the prevention of cataract.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is insufficient evidence that NAC reduces the progression
of cataract, nor reverses cataract.
Implications for research
The subject of non-surgical treatments for cataract remains topical
and valid. There is room for awell-designed, randomized, placebo-
controlled trial evaluating the efficacy of L-carnosine in the treat-
ment of cataracts. Future studies in this area should be well-pow-
ered, randomized, double-masked, placebo-controlled trials with
standardised quality of life outcomes and validated measures of
visual acuity, contrast sensitivity and glare. Follow-up should be a
minimum of two months.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Babizhayev 2009 Review article
Babizhayev 2011 Biochemistry article
Characteristics of studies awaiting assessment [ordered by study ID]
Babizhayev 2002
Methods Randomised, partly placebo-controlled study - some of the control group were untreated
Participants Country: Russia and United States
Number of people (eyes) randomized: 49 (76)
Average age: 65 +/- 7.0 years
49% women
Inclusion criteria:
• confirmed diagnosis of age-related cataract “according to the medical history, clinical observations and
epidemiological study”, availability for study of both lenses
• presence of a cataract in at least one eye
• cataracts judged not to require surgery in the near future (2 years) based on the patients’ visual needs and
ocular symptomatology
• 52 to 80 years of age
• pupillary dilation could be performed safely
Exclusion criteria:
• any other ocular disease such as glaucoma or clinically significant diabetic retinopathy
• previous laser retinal photocoagulation
• prior corneal or anterior segment surgery or corneal scars that would interfere with visualisation or
photography of the anterior segment
• mature cataract (VA less than 0.1) in both eyes, and were likely to be candidates for cataract surgery within 1
year
• monocular aphakia or secondary cataracts (e.g. cataracts associated with steroid intake, total body or local
irradiation, local inflammatory or degenerative process or ocular trauma)
• known or presumed hypersensitivity to any component of the ophthalmic preparations (active substances or
excipients)
• treated with drugs that could interfere with the trial
• wearing contact lenses
• concomitant ocular diseases
Interventions Intervention:
• Topical NAC 1% eye drops twice daily n = 26 (41 eyes)
Comparator:
• Placebo n = 13 (21 eyes)
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Babizhayev 2002 (Continued)
• No treatment n = 10 (14 eyes)
Unclear why some people received placebo and others did not
Outcomes All participants were evaluated at entry and followed up every 2 months for a 6-month period (trial 1), or at 6-
month intervals for a 2-year period (trial 2), for best-corrected visual acuity and glare testing. In addition, cataract was
measured using stereocinematographic slit-images and retro-illumination examination of the lens. Digital analysis of
lens images displayed light scattering and absorbing centres in two- and three-dimensional scales
Notes Date study conducted: not reported
Funding source: Innovative Vision Products, Inc, County of New Castle,Delaware, USA
Declarations of interest: No declarations of interest in the paper but NAC is marketed by the lead author under the
auspices of Innovative Vision Products
Trial id: not reported
Babizhayev 2004
Methods Randomised, placebo-controlled study
Participants Country: United States
Number of people (eyes) randomised: 65 (?)
Average age: 68 years (range 55 to 80)
47% women
Inclusion criteria:
• cataract in one or both eyes with best-corrected visual acuity of 20/40 or worse in one or both eyes as indicated
by the medical record
• no previous cataract surgery in either eye
• a primary diagnosis of cataract in the medical record
• living independently in the community
• legally licensed to drive and drove during the 5 years prior to enrolment
Exclusion criteria:
• known or presumed hypersensitivity to any component of the ophthalmic preparations (active substances or
excipients)
• treated with drugs that could interfere with the trial
The report also provided data on drivers without cataract. These data are not included in this review
Interventions Intervention:
• Topical NAC 1% eye drops twice daily (n = 35)
Comparator:
• Placebo (n = 30)
Outcomes All participants evaluated at entry and at 4 months with visual acuity and glare sensitivity
Better and worse eyes were reported and sometimes the eyes were averaged within person
Notes Date study conducted: not reported
Funding source: see declaration of interest
Decarations of interest: “This work was planned, organized, and supported by Innovative Vision Products, Inc. (County
of New Castle, DE). Innovative Vision Products, Inc. is a holder of the worldwide patent (including PCT International
Publication Number WO 2004/028536 A1) for the application of N-acetylcarnosine for the treatment of ophthalmic
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Babizhayev 2004 (Continued)
disorders, including cataracts”
Trial registration id: not reported
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D A T A A N D A N A L Y S E S
This review has no analyses.
A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MeSH descriptor Cataract
#2 cataract*
#3 eye*
#4 (#1 OR #2 OR #3)
#5 MeSH descriptor Carnosine
#6 carnosine*
#7 NAC
#8 (#5 OR #6 OR #7)
#9 (#4 AND #8)
Appendix 2. MEDLINE (Ovid) search strategy
1. randomized controlled trial.pt.
2. (randomized or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1-7
9. exp animals/
10. exp humans/
11. 9 not (9 and 10)
12. 8 not 11
13. cataract/
14. cataract$.tw.
15. eye$.tw.
16. or/13-15
17. carnosine/
18. carnosine$.tw.
19. NAC.tw.
20. or/17-19
21. 16 and 20
22. 12 and 21
The search filter for trials at the beginning of the MEDLINE strategy is from the published paper by Glanville 2006.
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Appendix 3. Embase (Ovid) search strategy
1. exp randomized controlled trial/
2. exp randomization/
3. exp double blind procedure/
4. exp single blind procedure/
5. random$.tw.
6. or/1-5
7. (animal or animal experiment).sh.
8. human.sh.
9. 7 and 8
10. 7 not 9
11. 6 not 10
12. exp clinical trial/
13. (clin$ adj3 trial$).tw.
14. ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$)).tw.
15. exp placebo/
16. placebo$.tw.
17. random$.tw.
18. exp experimental design/
19. exp crossover procedure/
20. exp control group/
21. exp latin square design/
22. or/12-21
23. 22 not 10
24. 23 not 11
25. exp comparative study/
26. exp evaluation/
27. exp prospective study/
28. (control$ or prospectiv$ or volunteer$).tw.
29. or/25-28
30. 29 not 10
31. 30 not (11 or 23)
32. 11 or 24 or 31
33. exp cataract/
34. cataract$.tw.
35. eye$.tw.
36. or/33-35
37. carnosine/
38. carnosine$.tw.
39. NAC.tw.
40. or/37-39
41. 36 and 40
42. 32 and 41
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Appendix 4. CINAHL (EBSCO) search strategy
S7 S3 AND S6
S6 S4 OR S5
S5 NAC
S4 carnosine*
S3 S1 OR S2
S2 cataract*
S1 (MH “Cataract”)
Appendix 5. AMED (Ovid) search strategy
1. cataract/
2. cataract$.tw.
3. eye$.tw.
4. or/1-3
5. carnosine$.tw.
6. NAC.tw.
7. or/5-6
8. 4 and 7
Appendix 6. ISRCTN search strategy
“Cataract AND (Carnosine OR NAC)”
Appendix 7. ClinicalTrials.gov search strategy
Cataract AND (Carnosine OR NAC)
Appendix 8. WHO ICTRP search strategy
Cataract AND (Carnosine OR NAC)
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Adverse effects were omitted from the protocol but have been included in the review. Using the GRADE approach was not included
in the protocol but was adapted for the review.
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